1. Search Result
Search Result
Results for "

neuron protective

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

5

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0076
    Bilobalide
    2 Publications Verification

    (-)-Bilobalide

    Apoptosis Autophagy Endogenous Metabolite Neurological Disease
    Bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba, inhibits the NMDA-induced efflux of choline with an IC50 value of 2.3 µM. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Exerts protective and trophic effects on neurons .
    Bilobalide
  • HY-105066
    Davunetide
    1 Publications Verification

    Microtubule/Tubulin Amyloid-β Neurological Disease
    Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity .
    Davunetide
  • HY-113468A
    3-O-Methyldopa
    1 Publications Verification

    3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA

    Drug Derivative Interleukin Related Neurological Disease Inflammation/Immunology
    3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
    3-O-Methyldopa
  • HY-N0076R

    Apoptosis Autophagy Endogenous Metabolite Neurological Disease
    Bilobalide (Standard) is the analytical standard of Bilobalide. This product is intended for research and analytical applications. Bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba, inhibits the NMDA-induced efflux of choline with an IC50 value of 2.3 μM. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Exerts protective and trophic effects on neurons .
    Bilobalide (Standard)
  • HY-165514A

    Cholinesterase (ChE) Neurological Disease
    Nafimidone hydrochloride is an anticonvulsant which inhibits cholinesterases, protects neurons, and ameliorates cognitive decline. Nafimidone can be utilized in epilepsy research .
    Nafimidone hydrochloride
  • HY-121406

    (Z)-FRG-8813

    Histamine Receptor Inflammation/Immunology
    (Z)-Lafutidine ((Z)-FRG-8813) is a potent histamine H2 receptor antagonist. (Z)-Lafutidine shows anti-secretory and gastroprotective activities .
    (Z)-Lafutidine
  • HY-N14405

    Others Neurological Disease
    Phenazostatin A is a phenazine Substance that has the protective effect of new neuron cells. Phenazostatin A can scavenge free radicals, protect N18-RE 105 nerve cells from glutamate toxicity, and inhibit lipid peroxidation. Phenazostatin A inhibits glutamate toxicity in N18-RE-105 cells with an EC50 of 0.34 μg/mL .
    Phenazostatin A
  • HY-N14406

    Others Neurological Disease
    Phenazostatin B is a phenazine Substance that has the protective effect of new neuron cells. Phenazostatin B can scavenge free radicals, protect N18-RE 105 nerve cells from glutamate toxicity, and inhibit lipid peroxidation. Phenazostatin B inhibits glutamate toxicity in N18-RE-105 cells with an EC50 of 0.33 μg/mL .
    Phenazostatin B
  • HY-117578

    Endogenous Metabolite Neurological Disease
    KB 5666 is a benzoxazine derivative with lipid peroxidation inhibitory activity. KB 5666 showed protective effects against post-ischemic neuronal death. KB 5666 effectively protected CA1 neurons when injected 5 minutes before or immediately after ischemia. KB 5666 also showed a dose-dependent protective effect when injected within 1 hour after ischemia. KB 5666 effectively prevented the significant decrease in microtubule-associated protein 2 immunoreactivity within the dendritic field of CA1 pyramidal cells. KB 5666 prevented the decrease in [3H]PDBu binding activity in different layers of the CA1 region after ischemia. The application of KB 5666 showed the ability to improve the cellular and functional consequences of ischemia .
    KB 5666
  • HY-113468AS1

    3-Methoxy-L-tyrosine-d3 hydrate; 3-O-Methyl-L-DOPA-d3 hydrate

    Isotope-Labeled Compounds Drug Metabolite Interleukin Related Neurological Disease Inflammation/Immunology
    3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .
    3-O-Methyldopa-d3 hydrate
  • HY-113468AS

    3-Methoxy-L-tyrosine-d3; 3-O-Methyl-L-DOPA-d3

    Isotope-Labeled Compounds Drug Metabolite Interleukin Related Neurological Disease Inflammation/Immunology
    3-O-Methyldopa-d3 (3-Methoxy-L-tyrosine-d3) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
    3-O-Methyldopa-d3
  • HY-160959

    nAChR Neurological Disease
    AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
    AN317

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: